INZY stock touches 52-week low at $1.14 amid market challenges

Inozyme Pharma Inc (INZY) stock has reached a 52-week low, trading at $1.14, representing just 15% of its 52-week high of $7.79. According to InvestingPro analysis, the company faces a tumultuous period marked by investor concerns and broader market headwinds. This latest price level reflects a significant downturn from previous valuations, with the stock experiencing a staggering 81.7% decline over the past year. The sharp decline underscores the volatility and challenges within the biopharmaceutical sector, though the company maintains a strong current ratio of 7.68 and holds more cash than debt on its balance sheet. Inozyme Pharma navigates through a critical phase of its business development and drug pipeline progress. Investors are closely monitoring the company’s strategic moves to rebound from this low point and recapture market confidence. InvestingPro subscribers can access 11 additional exclusive tips and comprehensive financial metrics to better evaluate INZY’s recovery potential.

In other recent news, Inozyme Pharma Inc. has reported positive interim results from its ENERGY 1 trial and Expanded Access Program, which evaluated the investigational drug INZ-701 in infants and young children with ENPP1 Deficiency. The data showed improvements in survival rates, heart function, and reductions in arterial calcifications, with no serious treatment-related adverse events reported. Additionally, Inozyme has completed enrollment for its ENERGY 3 pivotal trial, with topline data expected in early 2026. Meanwhile, Jefferies has initiated coverage on Inozyme with a Buy rating and set a price target of $26, highlighting the potential of INZ-701 based on promising Phase 2 study results. The firm noted the rapid normalization of pyrophosphate levels in adults and significant improvements in exploratory endpoints. Raymond (NSE:RYMD) James also maintained an Outperform rating on Inozyme, though it reduced the price target to $24 due to uncertainties related to anti-drug antibodies observed in the ENERGY 1 study. Despite these concerns, Raymond James remains confident in the treatment’s potential for ENPP1 deficiency patients. Additionally, Inozyme is working on refining the study protocol for its planned ASPIRE pivotal trial, focusing on severe complications of ABCC6 Deficiency in children, with initiation plans in early 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.